Location History:
- Sanchong, TW (2014 - 2015)
- New Taipei, TW (2019)
Company Filing History:
3 out of 685 
1 out of 832,880 Years Active: 2014-2019
Title: Ruei-Min Lu: Innovator in Cancer Therapeutics
Introduction
Ruei-Min Lu is a prominent inventor based in Sanchong, Taiwan. He has made significant contributions to the field of cancer therapeutics, particularly through his innovative antibody technologies. With a total of 3 patents, Lu's work focuses on developing methods for detecting and inhibiting tumor growth.
Latest Patents
One of Lu's latest patents is an anti-vascular endothelial growth factor receptor 2 (VEGFR2) antibody. This invention includes methods for detecting VEGFR2 and inhibiting tumor growth, tumor angiogenesis, and inducing cancer cell cytotoxicity. The patent describes an isolated antibody or an antigen-binding fragment that specifically binds to an epitope within the domain 1 or domain 3 of human VEGFR2. The epitope within domain 3 is located between amino acid residues 250 and 270. This antibody can be used in the manufacture of a medicament aimed at treating subjects in need of tumor growth inhibition.
Another significant patent by Lu is the anti-C-met antibody and its methods of use. This patent provides antibodies that bind to c-Met, along with related compositions and methods for cancer therapies and diagnostics. The antibodies can target various carcinomas, including those found in the lung, kidney, liver, stomach, breast, and brain.
Career Highlights
Ruei-Min Lu has worked at Academia Sinica, where he has been involved in groundbreaking research and development in the field of cancer therapeutics. His work has contributed to advancements in understanding and treating various types of cancer.
Collaborations
Lu has collaborated with notable colleagues, including Han-Chung Wu and Chiung-Yi Chiu. These collaborations have further enhanced the impact of his research and innovations in the field.
Conclusion
Ruei-Min Lu is a distinguished inventor whose work in cancer therapeutics has the potential to significantly impact patient care. His innovative patents and collaborations highlight his commitment to advancing medical science and improving treatment options for cancer patients.